RenovoRx, Inc.
RNXTHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, RenovoRx, Inc. (RNXT) is listed under Biotechnology. Valued at $99.3M, RNXT is a micro-cap name in its sector. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Market Cap
$99.3M
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-18.33
EPS (TTM)
$-0.31
EPS (Fwd)
$-0.12
ROE
-125.2%
ROA
-64.9%
Cash
$9.5M
Total Debt
$390,000
Free CF
-$6.6M
52W Change
104.3%
Annual Financials
Cash vs Debt
Where RNXT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RNXT finished 154.55% above its 150-day moving average ($0.99) and 159.79% above its 200-day moving average ($0.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNXT overbought or oversold?
At the September 3, 2026 close, RNXT's RSI(14) was 83.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.5M in cash comfortably exceeding the $390K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$6.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -125.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RNXT.